Mukka Proteins Approves ₹47 Crore Preferential Issue & ₹26.1 Crore Investment in Marine Firms
Mukka Proteins will issue 2 crore warrants at ₹23.50 each, raising ₹47 crore. The company will also invest ₹11.1 crore in Delta Marine Products and ₹15 crore in Aqua Marine. These strategic investments aim to expand the company's core business. The Board approved these decisions on June 12, 2026.
The preferential issue of warrants and strategic investments in related businesses represent substantial financial and strategic moves that could significantly impact the company's future growth and market position.
The company is raising significant capital through a preferential issue and making strategic investments to expand its core business, which are positive developments.
Mukka Proteins Limited announced today, June 12, 2026, that its Board of Directors has approved the issuance and allotment of up to 2,00,00,000 (Two Crore) Fully Convertible Warrants on a preferential basis to identified Non-Promoter Category individuals and entities. The issue price for these warrants is fixed at ₹23.50 per warrant, aggregating up to ₹47,00,00,000 (Rupees Forty-Seven Crore Only).
Each warrant is convertible into one fully paid-up equity share of face value ₹1 each, at the option of the warrant holder, within 18 months from the allotment date, subject to shareholder and regulatory approvals. The 'Relevant Date' for determining the minimum issue price is June 12, 2026. The Board also approved a draft Postal Ballot Notice and set the cut-off date for e-voting as June 10, 2026, with the e-voting period scheduled from June 13, 2026, to July 12, 2026.
Furthermore, Mukka Proteins will make strategic investments in two partnership firms: Delta Marine Products and Aqua Marine. The company will invest up to ₹11,10,00,000 (Rupees Eleven Crores Ten Lakhs Only) in Delta Marine Products and up to ₹15,00,00,000 (Rupees Fifteen Crores Only) in Aqua Marine, by way of capital contribution. Both investments are intended to expand the company's core business, focusing on capacity expansion and operational optimization. The indicative time period for the completion of these acquisitions is September 30, 2026. The Board meeting commenced at 11:10 a.m. and concluded at 5:00 p.m.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.